Elanco Animal Health Incorporated (ELAN) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate.
Is Elanco Animal Health Incorporated stock overvalued or undervalued in 2026?
As of November 2, 2026, Elanco Animal Health Incorporated (ELAN) trades at $24.10 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Elanco Animal Health Incorporated
Market cap $12B · 52 weeks $20 – $27 (10 % below the high) · P/E no earnings · 2027 est. P/E 19.0× · Dividend none · Next earnings November 6, 2026 · expected EPS $0.20 · Closing price, Nov 2 · accounts published Aug 5.
- Valuation: EV/EBITDA 19.9× (no earnings).
- Business: ROIC 4 % (weak).
- Balance sheet: Net debt/EBITDA 5.1× (fragile).
- Earnings: 7 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 0 of 4 pass
- R&D / Revenue 7.8 %, fails.
- Gross margin 43.5 %, fails.
- ROIC 3.9 %, fails.
- Net debt / EBITDA 5.1×, fails.
Against its peers (reference peers) — Elanco Animal Health Incorporated: P/E —; EV/EBITDA 19.9×; ROIC 3.9 %; $12.0B. Zoetis Inc. (P/E 13.7×; EV/EBITDA 10.6×; ROIC 21.6 %; $34.4B), IDEXX Laboratories, Inc. (P/E 45.6×; EV/EBITDA 32.7×; ROIC 47.8 %; $52.9B), Neogen Corporation (P/E —; EV/EBITDA 30.3×; ROIC -0.2 %; $2.6B).
Profitability
| Return on Equity | -3.02% |
| Return on Invested Capital | 3.92% |
| Return on Assets | -1.47% |
| Gross Margin | 52.59% |
| Operating Margin | 9.20% |
| Net Margin | -3.96% |
Financial Health
| Debt / Equity | 0.59 |
| Current Ratio | 2.05 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.34 |
Price Performance
| 1 month | +8.85% |
| 3 months | -8.09% |
| Year-to-date | +6.50% |
| 1 year | +5.47% |
| 3 years | +150.78% |
| 5 years | -26.68% |
Related companies: MRK · IDXX · NEOG · ZTS
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ELAN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks